Brentuximab Vedotin

About

Therapy type: Targeted therapy

Therapy strategy: target CD30 antigens

Mappings

NCI Thesaurus: Brentuximab Vedotin (ncit:C66944)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD30 + Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+) CD30 + Anaplastic Large Cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin, Dacarbazine, Doxorubicin, Vinblastine
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Cutaneous T-cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin, Cisplatin, Cytarabine, Etoposide
Sensitivity (+) CD30 + Cutaneous T-cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 +, HER2-negative Hodgkin Lymphoma Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide
Sensitivity (+) CD30 + Hodgkin Lymphoma Bendamustine, Brentuximab Vedotin